AA
MLYS icon

ALPS Advisors’s Mineralys Therapeutics MLYS Stock Holding History

ALPS Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.4M Buy
88,976
+24,557
+38% +$674K 0.01% 466
2026
Q1 		$1.75M Sell
64,419
-568
-0.9% -$16.7K 0.01% 432
2025
Q4 		$2.36M Buy
+64,987
New +$2.61M 0.01% 372
2025
Q2 		– Sell
-34,664
Closed -$550K – 1047
2025
Q1 		$550K Sell
34,664
-5,584
-14% -$64.2K ﹤0.01% 577
2024
Q4 		$495K Buy
40,248
+1,984
+5% +$25.9K ﹤0.01% 606
2024
Q3 		$463K Sell
38,264
-471
-1% -$5.7K ﹤0.01% 621
2024
Q2 		$453K Buy
38,735
+9,746
+34% +$123K ﹤0.01% 598
2024
Q1 		$374K Buy
28,989
+2,314
+9% +$28.6K ﹤0.01% 691
2023
Q4 		$229K Sell
26,675
-3,473
-12% -$27.3K ﹤0.01% 938
2023
Q3 		$287K Buy
30,148
+117
+0.4% +$1.53K ﹤0.01% 896
2023
Q2 		$512K Buy
+30,031
New +$449K ﹤0.01% 610

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ALPS Advisors's MLYS Position: Q2 2026 in Review

ALPS Advisors increased its Mineralys Therapeutics (MLYS) stake by 38% in Q2 2026, buying an estimated $674K and bringing the position to 88,976 shares worth $2.4M. The position accounts for 0.01% of the portfolio, ranked #466.

ALPS Advisors first reported a position in MLYS in Q2 2023 and has held it in 11 quarters since. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • ALPS Advisors held 88,976 shares of Mineralys Therapeutics worth $2.4M as of Q2 2026.
  • ALPS Advisors bought 24,557 Mineralys Therapeutics shares in Q2 2026, an estimated $674K.
  • Mineralys Therapeutics made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #466 holding.
  • ALPS Advisors first reported a position in Mineralys Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.